SPI-POZ-202: Poziotinib for EGFR/HER2 Exon 20 Mutated Non-Small Cell Lung Cancer
Condition: Non-Small Cell Lung Cancer
Sponsor: Spectrum Pharmaceuticals, Inc.
Protocol SPI-POZ-202: A phase 2 trial of Tyrosine Kinase inhibitor Poziotinib for patients with metastatic Non-small Cell Lung cancer containing EGFR or HER2 exon 20 mutation that have undergone at least one prior line of therapy for metastatic disease.
For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: 631-675-5075.